Toronto, ON – June 4, 2026 – The Canadian Nuclear Isotope Council (CNIC) is pleased to welcome Transmutex, an advanced nuclear engineering company developing high-power particle accelerator technologies for radioisotope generation and nuclear waste transmutation, to its network of leaders in the isotope sector. Based in Switzerland, Transmutex brings a highly specialized international perspective to the CNIC’s network as Canada continues to strengthen its isotope ecosystem and examine the role advanced nuclear technologies play in supporting long-term supply resilience.
Transmutex’s medical isotope platform, HI-BEAM (High Energy Breakthrough Engineering for Advanced Medicine), is a high-power particle accelerator-based platform engineered specifically for industrial-scale isotope production. A single HI-BEAM facility is designed to produce alpha-emitting isotopes such as Actinium-225, Radium-223, and Lead-212, alongside a broad panel of imaging isotopes. This directly addresses the structural supply shortage that has, to date, limited the broader deployment of next-generation targeted alpha therapies.
By leveraging accelerator-based production at industrial scale, the platform is intended to complement the large number of isotopes already produced in conventional nuclear reactors by enabling the production of isotopes that cannot readily be produced in existing reactor-based systems, and to support more reliable and more cost-efficient isotope supply pathways as global demand for targeted radiotherapies increases.
The same accelerator-driven approach also underpins Transmutex’s longer-horizon work on spent nuclear fuel transmutation through its START system (Subcritical Transmuting Accelerated Regenerative Technology). For Canada’s isotope sector, the most immediate relevance is the production capacity HI-BEAM is designed to deliver as targeted alpha therapies approach regulatory approval at the end of the decade.
“Transmutex’s work expands how we think about the possibilities of future isotope production,” said Melody Greaves, Executive Director of the CNIC. “Their work considers how advanced nuclear systems can produce isotopes, expanding global isotope production pathways to ensure reliability of supply for future research and patient access to life-changing isotopes. This kind of thinking will support Canada’s isotope sector as we plan for increased capacity and use and prepare to double production by 2030.”
By joining the CNIC, Transmutex adds accelerator-driven nuclear expertise to a national network that spans isotope production, nuclear medicine, research, infrastructure, and policy. Its membership reflects the growing importance of international collaboration as the isotope sector looks beyond today’s production systems and considers how next-generation nuclear technologies can strengthen access to the isotopes patients and industries depend on in Canada and globally.
“HI-BEAM combines high-power accelerator technology with target design expertise to produce alpha-emitting isotopes at scale, together with a broad portfolio of medical and industrial isotopes. Solving the supply constraint will help broaden access to these highly effective next-generation cancer therapies while supporting a more scalable and economically sustainable supply model for the sector. Canada’s accelerator science and radiopharmaceutical infrastructure, including institutions represented within the CNIC, make it a natural home for this kind of capability. We are pleased to be joining the network,” said Franklin Servan-Schreiber, CEO of Transmutex.
To learn more about Transmutex, visit transmutex.com
About the Canadian Nuclear Isotope Council
The Canadian Nuclear Isotope Council (CNIC) is an independent, not-for-profit advocacy and member services organization. The CNIC supports over 120 members from across science, academia, healthcare, and nuclear-sector organizations dedicated to maintaining Canada’s position as a global leader in the production of life-saving isotopes. The CNIC raises awareness and advocates for long-term policies that support health-care innovation and will save countless lives for decades to come.
To learn more about the CNIC, visit www.CanadianIsotopes.ca and follow us on Facebook, Twitter, and LinkedIn, or please contact:
Evan Cameron
Manager, Public Affairs and Communications
Canadian Nuclear Isotope Council
evan.cameron@canadianisotopes.ca